Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has said that the Court of Appeals for the Federal Circuit has upheld the two main US patents covering Celebrex, the company's pain medicine. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA.
Subscribe to our email newsletter
The panel has ruled that the patents covering the active ingredient and a pharmaceutical composition thereof are valid, enforceable and infringed by the generic manufacturer’s product. In the same decision, the Court also ruled that a third patent covering the use in the treatment of inflammation was invalid.
The decision prohibits Teva from launching a competitor drug in the US until May 2014. Either party may request a rehearing by the Court of Appeals or a review by the US Supreme Court.